Savient Pharmaceuticals Enterprise Value:
168.00M for May 17, 2013Savient Pharmaceuticals Historical Enterprise Value Data
Pro Data ExportThere is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| May 17, 2013 | 168.00M |
| May 16, 2013 | 168.74M |
| May 15, 2013 | 169.48M |
| May 14, 2013 | 176.50M |
| May 13, 2013 | 177.16M |
| May 10, 2013 | 179.82M |
| May 9, 2013 | 179.82M |
| May 8, 2013 | 178.72M |
| May 7, 2013 | 179.08M |
| May 6, 2013 | 179.90M |
| May 3, 2013 | 180.63M |
| May 2, 2013 | 180.19M |
| May 1, 2013 | 182.02M |
| April 30, 2013 | 181.76M |
| April 29, 2013 | 182.78M |
| April 26, 2013 | 183.16M |
| April 25, 2013 | 183.51M |
| April 24, 2013 | 182.92M |
| April 23, 2013 | 182.78M |
| April 22, 2013 | 181.74M |
| April 19, 2013 | 181.96M |
| April 18, 2013 | 180.16M |
| April 17, 2013 | 180.93M |
| April 16, 2013 | 181.25M |
| April 15, 2013 | 180.74M |
| April 12, 2013 | 181.67M |
| April 11, 2013 | 182.04M |
| April 10, 2013 | 182.78M |
| April 9, 2013 | 181.61M |
| April 8, 2013 | 181.39M |
| April 5, 2013 | 182.40M |
| April 4, 2013 | 184.10M |
| April 3, 2013 | 184.25M |
| April 2, 2013 | 182.73M |
| April 1, 2013 | 184.10M |
| March 28, 2013 | 186.15M |
| March 27, 2013 | 186.15M |
| March 26, 2013 | 184.26M |
| March 25, 2013 | 183.92M |
| March 22, 2013 | 186.82M |
| March 21, 2013 | 183.10M |
| March 20, 2013 | 182.52M |
| March 19, 2013 | 181.76M |
| March 18, 2013 | 190.22M |
| March 15, 2013 | 193.14M |
| March 14, 2013 | 193.14M |
| March 13, 2013 | 193.14M |
| March 12, 2013 | 192.77M |
| March 11, 2013 | 193.43M |
| March 8, 2013 | 194.80M |
About Enterprise Value
Click "Learn More" below to see how YCharts calculates Enterprise Value.
Enterprise Value (EV) is a valuation metric alternative to traditional market capitalization that reflects the market value of an entire business. Like market cap, EV is a measure of what the market believes a company is worth. Enterprise value captures the cost of an entire business, including debt and equity. It is a sum of claims of all preferred shareholders, debt holders, security holders, common equity holders, and minority shareholders - unlike market cap, which only captures the total value of common equity securities.
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Learn More
SVNT Enterprise Value Benchmarks
| Companies | |
|---|---|
| Corcept Therapeutics | 112.32M |
| BioTime | 236.58M |
| Omeros Corporation | 130.93M |
SVNT Enterprise Value Rankings
| Overall |
57th percentile 3233 of 7593 |
| Sector |
48th percentile 334 of 650 in Healthcare |
| Industry |
57th percentile 100 of 237 in Biotechnology |
SVNT Enterprise Value Range, Past 5 Years
| Minimum | 68.73M | Dec 1 2008 |
| Maximum | 1.474B | Oct 8 2010 |
| Average | 516.76M |
SVNT News
Street Insider May 15
